Drug Delivery · 2021 · 30 citations · 35 references
PharmacyPharmaceuticsPharmacologyBioavailabilityDrug DeliveryOphthalmic Drug DeliveryCorneal Drug DeliveryOcular BioavailabilityOcular NanocarriersOphthalmic Formulation DesignOphthalmic FormulationsOphthalmic SolutionsBioavailability Of Ocular DrugsControlled Drug ReleaseDrug Delivery To The EyeNanoparticle-based Ophthalmic FormulationsNeovascularizationOcular Drug Permeation EnhancementOphthalmic MicroemulsionsSolubility-limited Bioavailability
corneal permeation study. Human corneal epithelial cells (HCECs) toxicity study showed no toxicity with NAR-ME, which is consistent with the result of ocular irritation study. NAR-ME had high bioavailability 1.45-fold, 2.15-fold, and 1.35-fold higher than NAR-Susp in the cornea, conjunctiva, and aqueous humor, respectively. Moreover, NAR-ME (0.5% NAR) presented efficacy comparable to that of dexamethasone (0.025%) in the inhibition of CNV in mice CNV model induced by alkali burning, resulting from the attenuation of corneal vascular endothelial growth factor (VEGF) and matrix metalloproteinase (MMP-14) expression. In conclusion, the optimized NAR-ME formulation demonstrated excellent physicochemical properties and good tolerance, enhanced ocular bioavailability and corneal permeability. This formulation is promising, safe, and effective for the treatment of CNV.
35
Formulation design of microemulsion for dermal delivery of penciclovir
Weiwei Zhu, Aihua Yu, Weihong Wang et al. · International Journal of Pharmaceutics · 2008 · 143 citations